Výsledky vyhledávání - "Ellen A. Ronnen"

Building a SW program in a private hem/onc practice: Using the PHQ-9 as a starting point

Autor: Neshama L Marcus, Shannon Woerner, Jake Canavan, Kanokrose Rattanaudom, John Papandrea, Ellen A. Ronnen

Publikováno v: Journal of Clinical Oncology. 40:266-266

266 Background: Hematology/oncology patients historically have high need for social work support. Community practices lack the structure and financial support of hospital practices, often hindering the growth of social work programs. PHQ-9 is a 9-que

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d2ee592b02e56943a59614337421e6e
https://doi.org/10.1200/jco.2022.40.28_suppl.266

Zobrazit plný text záznamu

Is ECOG-PS ≥3 appropriate to guide rehabilitation referral decisions? Using patient-reported outcome measures to examine the prevalence of functional disability in patients with ECOG-PS 0-2

Autor: Kelley C Wood, Mary Hidde, Tiffany Kendig, Ellen A. Ronnen, Rachel Carroll, Smith Giri, Grant Richard Williams, Mackenzi Pergolotti

Publikováno v: Journal of Clinical Oncology. 40:e18724-e18724

e18724 Background: Outpatient physical or occupational therapy (PT/OT) can optimize cancer patients’ performance status and ability to complete instrumental activities of daily living (IADL). The American College of Sports Medicine recommends refer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ddd7209bd108f8848b92f4188c1e34a
https://doi.org/10.1200/jco.2022.40.16_suppl.e18724

Zobrazit plný text záznamu

Prevalence of frailty for middle-aged and older adults starting a new line of systemic cancer treatment: Is age just a number?

Autor: Mackenzi Pergolotti, Kelley C Wood, Mary Hidde, Tiffany Kendig, Grant Richard Williams, Smith Giri, Ellen A. Ronnen, Rachel Carroll

Publikováno v: Journal of Clinical Oncology. 40:12054-12054

12054 Background: Frailty is associated with adverse outcomes and increased risk of mortality for older adults (>60 years) with cancer. Geriatric assessment (GA) has gained popularity in routine cancer care as a clinical tool to screen for frailty in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6fc06e17a71ed05faf91f88f00332f87
https://doi.org/10.1200/jco.2022.40.16_suppl.12054

Zobrazit plný text záznamu

Evaluation of compliance of next-generation sequencing (NGS) testing in stage IV genitourinary (GU) cancer patients (pts) and the effect of an EHR prompt (EP) on increasing frequency

Autor: Sydney E. Cobrin, Percy Yeung, Carina Cedeno, Stephanie Marks, Ellen A. Ronnen

Publikováno v: Journal of Clinical Oncology. 40:48-48

48 Background: Previous reports have found that NGS testing on stage IV GU cancer patients is performed less commonly than expected based on the prevalence of GU tumors in comparison to other tumor types. In addition, most of the data on NGS testing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a986bd1fef363e64a80b4fc18c089dd
https://doi.org/10.1200/jco.2022.40.6_suppl.048

Zobrazit plný text záznamu

Utilization of next generation sequencing (NGS) in stage IV gastrointestinal (GI) cancer patients (pts) and efficacy of electronic reminder notification (ERN) in improving utilization of NGS in the private practice community-based setting

Autor: Kapil Foster, Carina Cedeno, Stephanie Marks, Percy Yeung, Ellen A. Ronnen

Publikováno v: Journal of Clinical Oncology. 40:73-73

73 Background: NGS testing allows for identification of genetic mutations/alterations that can be important in determining treatment options for advanced cancer pts. The National Comprehensive Cancer Network (NCCN) includes NGS testing as part of sta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8dcdc69e700f226762b9ec43d27eaf50
https://doi.org/10.1200/jco.2022.40.4_suppl.073

Zobrazit plný text záznamu

Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards

Autor: Mary K. Anderson, Michael Brodersen, Stuart Genschaw, Gury Doshi, Eileen Peng, Wayne Ormsby, Patty Davis, Melissa S. Dillmon, Howard Cohen, Issam Makhoul, Steven L D Amato, Bill Wimbiscus, Rajiv Panikkar, Michael J. Reff, Luis E. Raez, Ellen A. Ronnen, Erin B. Kennedy

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(6)

PURPOSE To provide standards for medically integrated dispensing of oral anticancer drugs and supportive care medications. METHODS An Expert Panel was formed, and a systematic review of the literature on patient-centered best practices for the delive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6166c01823dc75f6317ce829a674b1cf
https://pubmed.ncbi.nlm.nih.gov/31815576

Zobrazit plný text záznamu

Co-management of elevated glucose in chemotherapy patients in the community: Working with primary care physicians

Autor: Ellen Shander, Beth Balinski, Eileen Ruey-Fun Peng, Sharon Ryan, Ellen A. Ronnen, Melissa Isabel Cruz

Publikováno v: Journal of Clinical Oncology. 37:53-53

53 Background: Approximately 8-18% of oncology patients also have diabetes. A diabetes diagnosis increases the risk of recurrence by 21% and decreases both overall and cancer-related 5-year survival. Chemotherapy has also been associated with hypergl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bebd8eecdce2b23721c8f2de44707ba2
https://doi.org/10.1200/jco.2019.37.27_suppl.53

Zobrazit plný text záznamu

Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Autor: Michelle S. Ginsberg, Carlos D. Flombaum, Hani Hassoun, Patricia Fischer, Sujata Patil, Susanne Velasco, Michael Baum, Ellen A. Ronnen, Robert J. Motzer, Darren R. Feldman, Nicole Ishill

Publikováno v: Journal of Clinical Oncology. 27:1432-1439

Purpose Both bevacizumab and sunitinib target the vascular endothelial growth factor pathway and demonstrate activity against advanced renal cell carcinoma (RCC). In this phase I study, the maximum-tolerated dose (MTD) and safety of sunitinib in comb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dbf47a47e2d14af675f8b2ef596447b
https://doi.org/10.1200/jco.2008.19.0108

Zobrazit plný text záznamu

Signal Transduction Inhibitors in Renal Cell Carcinoma

Autor: Ellen A. Ronnen, Robert J. Motzer, Saby George, Ronald M. Bukowski

Publikováno v: Clinical Management of Renal Tumors ISBN: 9781588292513

Metastatic renal cell carcinoma (RCC) has been characterized by a resistance to systemic chemotherapy and poor overall survival. Cytokine therapy, the mainstay of treatment, provides responses in a minority of patients. The discovery of the VHL tumor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b75620e788f0c3cf3fdc0250ec550ef
https://doi.org/10.1007/978-1-60327-149-3_25

Zobrazit plný text záznamu

Treatment outcome for metastatic papillary renal cell carcinoma patients

Autor: Victor E. Reuter, Robert J. Motzer, Lesley Spodek, Jennifer Bacik, G. Varuni Kondagunta, Ellen A. Ronnen, Nicole Ishill, Paul Russo

Publikováno v: Cancer. 107(11)

BACKGROUND. Most clinical trial reports in metastatic renal cell carcinoma (RCC) do not distinguish between histologic subtypes, making it difficult to assess specific treatment efficacy. The current retrospective study sought to define clinical feat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dd7a65bf2f35b9d54862b5491836630
https://pubmed.ncbi.nlm.nih.gov/17083126

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání